Table 2.
Treatment characteristics and clinical outcomes.
| Characteristic | All patients (n = 181) | SIRI ≤ 1.78 (n = 96) | SIRI > 1.78 (n = 85) | P value |
|---|---|---|---|---|
| RT technique, n (%) | ||||
| 3D-CRT | 94 (51.9) | 49 (51.0) | 45 (52.9) | 0.79 |
| SIB-IMRT | 87 (48.1) | 47 (49.0) | 40 (47.1) | |
| RT dose, n (%) | ||||
| 60 Gy | 97 (53.6) | 50 (52.1) | 47 (55.3) | 0.62 |
| 70 Gy | 84 (46.4) | 46 (47.9) | 38 (44.7) | |
| Adjuvant TMZ cycles, n (%) | ||||
| 1-5 | 48 (28.8) | 23 (28.8) | 25 (28.7) | 0.96 |
| 6-12 | 119 (71.2) | 57 (71.2) | 62 (71.3) | |
| Salvage treatment, n (%) | ||||
| None | 83 (45.9) | 44 (45.8) | 39 (45.9) | 0.54 |
| Unknown | 7 (3.9) | 4 (4..2) | 3 (3.5) | |
| SNS alone | 19 (10.5) | 10 (10.4) | 9 (10.7) | |
| SRS/SRT | 16 (8.8) | 8 (8.4) | 8 (9.4) | |
| SNS + SRS/SRT | 8 (4.4) | 5(5.2) | 3 (3.5) | |
| SNS + Ctx | 15 (9.3) | 8 (8.4) | 7 (8.2) | |
| SNS + SRS + Ctx | 8 (4.4) | 4 (4.2) | 4 (4.7) | |
| Ctx alone | 25 (12.8) | 13 (13.4) | 12 (14.1) | |
| Need for hospitalization, n (%) | ||||
| Yes | 29 (16.0) | 10 (10.4) | 19 (22.4) | 0.002 |
| No | 152 (84.0) | 86 (89.6) | 66 (77.6) | |
| Hospitalization duration, days | 6 (1-17) | 4 (1-8) | 9 (3-17) | < 0.001 |
Abbreviations: SIRI: systemic immune response index; RT: radiotherapy; 3D-CRT: 3-dimensional conformal radiotherapy; SIB-MRT: simultaneous integrated boost intensity-modulated radiotherapy; TMZ: temozolomide; SNS: salvage neurosurgery; SRS: stereotactic radiosurgery; SRT: stereotactic radiotherapy; Ctx: chemotherapy.